IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.
About IPO Scanner
IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.
Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.
Details of client bank account
For any query / feedback / clarifications, email at
[email protected].
Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.
© 2026 IPO Scanner. All rights reserved.
Want to stay updated?Subscribe to our newsletter
ROKIT America, Inc.
ROKIT America is committed to extending human healthspan and enhancing quality of life in an aging society through its proprietary Reverse Aging Product which is intended to support cellular health and aging-related biological processes at the molecular level, and its artificial intelligence hyper-personalized Organ Regeneration Platform, a proprietary technology developed by our parent company, ROKIT Healthcare, which is intended to provide regenerative medicine solutions in the Americas.
Since its founding in 2019, the Company has focused on the research and development of dietary supplements centered around β-Nicotinamide Mononucleotide (“NMN”). We have launched a range of NMN-based products into global markets, including the United States.
Our flagship product line, ROKIT AMERICA NMN, combines NMN with pterostilbene, a naturally occurring antioxidant.
Ticker, listing venue and issuer profile
Pricing terms and IPO milestones
Key valuation ratios and metrics
Balance sheet strength and liquidity
Margins and return on capital
Historical financial performance
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| S-1/A | May 8, 2026 | [Amend] General form for registration of securities under the Securities Act of 1933 |
| S-1 | Apr 15, 2026 | General form for registration of securities under the Securities Act of 1933 |
| DRS/A | Apr 2, 2026 | [Amend] [Cover] Draft Registration Statement |
| DRS/A | Mar 11, 2026 | [Amend] [Cover] Draft Registration Statement |
| DRS/A | Jan 16, 2026 | [Amend] [Cover] Draft Registration Statement |
| DRS | Oct 2, 2025 | [Cover] Draft Registration Statement |
Contact and headquarters details
Key executives and officers
Seok Hwan You
Chief Executive Officer and Chairman of the Board of Directors
Ha Young Kim
Chief Financial Officer and Director
Seong Mo Jee
Chief Strategy Officer
Min Gu Lee
Chief Medical Officer
Won Kyung Choi
Chief Technology Officer
Woo Young Kim
Chief Operation Officer
Min Kyoung Choi
Chief Legal Officer

Issue Size
$25.00M
Price Range
$8.50 - $10.50
Shares
27.63M o/s · 2.63M offered
Sector
Consumer Staples
Filed
Apr 15, 2026